A Health Impact Fund pilot that pays for measured health gain instead of price
Companies could choose to sell a new cancer drug at cost worldwide and instead be paid from a pooled fund according to how much health it actually delivers.
The Health Impact Fund proposal: an optional, government-financed pool that pays registered products annually for ten years in proportion to their measured health impact (quality-adjusted life years gained across all countries), on condition that the product is sold at the cost of manufacture everywhere. For oncology this rewards drugs that deliver large gains to many patients, including in low-income countries, rather than drugs that extract high prices from few. An oncology-only pilot with a few billion dollars and two or three products would test measurement feasibility and industry appetite.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaA joint price negotiation bloc for middle-income countries, modelled on Beneluxa
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaBuy out the patent on a curative cancer drug and sell it at generic prices
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaGrant extra exclusivity only in exchange for binding low prices in poorer countries
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaBundled episode payments for cancer care with bonuses for guideline concordance
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaDisclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares Incentives reward me-too drugs and marginal gains, Prices and value.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Prices and value, Most of the world has almost no cancer care.